Aegerion Pharmaceuticals Inc. rose after a U.S. regulatory staff report said a plan to manage the risks of the company’s drug supports its approval in adults with the most life-threatening forms of severely high cholesterol.
Like any patient at risk of a heart attack, Kennedi Thompson has been counseled by her doctor to eat a low-fat diet and take prescription statins to reduce her cholesterol. Unlike most others facing heart disease, Kennedi is 3 years old.
Affymax Inc. surged the most in 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen Inc. and Johnson & Johnson for patients with chronic kidney disease.
Affymax Inc. surged the most in 16 months after winning a U.S. advisory panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson.
Vivus Inc. failed to win U.S. approval to introduce the first new prescription diet pill in more than a decade, becoming the second experimental obesity treatment rejected by regulators in the past two weeks.